




# Sigachi Industries Limited

Earnings Presentation

Q1-FY23






# Company Overview

- Sigachi Industries Limited (Sigachi), incorporated in the year 1989, is one of the leading manufacturers of Micro Crystalline Cellulose (MCC) in the world.
- Sigachi manufactures high-quality cellulose-based excipients, which predominantly find usage in the pharmaceutical, supplement and food industries.
- The company has created a niche in manufacturing highly innovative pre-formulated excipients & 60+ widely used excipients of international quality standards.
- With two facilities in Gujarat and one in Telangana, Sigachi ensures supply chain reliability for its customers in India and across the globe.
- Sigachi has a global sales and distribution network and exports to more than 40 countries across Asia, Australia, American Continent, Europe and Middle East.
- From its state-of-the-art R & D facility the company ensures continuous innovation to efficiently meet evolving customer demands.
- The company also has an agreement with Gujarat Alkalies and Chemicals Limited (“GACL”) for operating and managing the manufacturing units owned by GACL and for contract manufacturing of sodium chlorate, stable bleaching powder and poly aluminum chloride.

Revenue (INR Mn) & EBITDA Margins (%)





# Key Strengths



**One of the leading manufacturers of MCC in India with over 30 years' experience:**

- Made advancements in development of MCC and positioned as one of the key manufacturing players globally
- Technical capabilities, capable R&D Division and manufacturing infrastructure, gives a first mover advantage in India




**Presence across diverse industry verticals with long standing relationship with customers :**

- Customization of products based on customer specifications and requirements
- Track record of consistent delivery of quality and cost-effective products and solutions through strategic alignment of key customers' goals over the years



**Pan India and International market presence:**

- A long-standing market presence in India and internationally
- Export products to 41 countries including Australia, USA, South America, U.K., Poland, Italy, Denmark, China, Colombia, Bangladesh, to name a few



**Growth led by continuous investment and focus on R&D:**

- Regular investments in R&D to expand the product offerings and to streamline manufacturing process
- 2 R&D Division and 2 in-house laboratories
- The laboratory in the Jhagadia R&D Division has been approved and has received an accreditation by DSIR to undertake R&D activities



**Comprehensive product portfolio enables to serve diverse end-use applications:**

- Customize the usage and application of the products to various industries including but not limited to pharmaceutical, food, nutraceuticals and cosmetics
- Manufacture MCC in various grades ranging from 15 microns to 250 microns



**Strategically located manufacturing facilities**

- Set up 3 multi locational manufacturing units namely, Hyderabad, Telangana ("Unit I"), Jhagadia, Gujarat ("Unit II") and Dahej, Gujarat ("Unit III") which helps provide timely, efficient and customized delivery of the products in terms with the specific demographic needs



# Financial Overview

---

## Q1-FY23 Financial Highlights

<p><b>INR 783 Mn</b> Operating Income +43% YoY</p>	<p><b>INR 163 Mn</b> Operating EBITDA +34% YoY</p>	<p><b>20.82%</b> EBITDA Margin -140 Bps YoY</p>
<p><b>INR 128 Mn</b> Net Profit +42% YoY</p>	<p><b>16.35%</b> PAT Margins -4 Bps YoY</p>	<p><b>INR 4.17/Share</b> Diluted EPS +7% YoY</p>

## Q1-FY23 Operational Highlights

- Revenue growth driven by increased demand for MCC across all industries, with volume growth of ~10% and realisation growth of ~19% on a QoQ basis.
- Export sales increased to 75.43% in Q1-FY23 as compared to 73.60% in Q1-FY22 with continuous efforts to enhance the global client base through marketing efforts and product customization.
- Focus on high margin yielding product mix with cost-effective manufacturing processes, effective management of inventory resulted in improvement of EBITDA and Profitability on a QoQ basis.
- The consumption of material reduced to 47% from 51% in Q1-FY22 due to adoption of cost effective process and favorable product mix.
- Company expects the growth trend to continue with current profitability at sustainable levels.
- Furthermore, capacities of around 7,000 MT will be added during the latter part of FY23 which will contribute to additional revenue growth in the coming financial years.
- Company is constantly thriving to improve upon its R&D capabilities and cost-effective manufacturing processes and thereby remain as a manufacturer of choice with highest quality standards.



# Quarterly Consolidated Financial Performance

Particulars (INR Mn)	Q1-FY23	Q1-FY22	Y-o-Y	Q4-FY22	Q-o-Q
Operational Revenue	783	549	42.6%	725	8.0%
Total Expenses	620	427	45.2%	579	7.1%
<b>EBITDA</b>	<b>163</b>	<b>122</b>	<b>33.6%</b>	<b>146</b>	<b>11.6%</b>
<i>EBITDA Margin (%)</i>	<i>20.82%</i>	<i>22.22%</i>	<i>(140) Bps</i>	<i>20.13%</i>	<i>69 Bps</i>
Depreciation and amortisation	8	6	33.3%	8	NA
Finance costs	5	2	NA	5	NA
Other Income	16	2	NA	17	(5.9)%
<b>PBT</b>	<b>166</b>	<b>116</b>	<b>43.1%</b>	<b>151</b>	<b>9.9%</b>
Tax Expense	38	26	46.2%	35	8.6%
<b>PAT</b>	<b>128</b>	<b>90</b>	<b>42.2%</b>	<b>116</b>	<b>10.3%</b>
<i>PAT Margin (%)</i>	<i>16.35%</i>	<i>16.39%</i>	<i>(4) Bps</i>	<i>16.00%</i>	<i>35 Bps</i>
Diluted EPS	4.17	3.90	6.9%	4.49	(7.1)%



# Historical Consolidated Financial Performance

Particulars (INR Mn)	FY20	FY21	FY22	Q1-FY23
Operational Revenue	1,391	1,928	2,503	783
Total Expenses	1,143	1,540	1,972	620
EBITDA	248	388	531	163
<i>EBITDA Margin (%)</i>	<i>17.83%</i>	<i>20.12%</i>	<i>21.21%</i>	<i>20.82%</i>
Depreciation and amortisation	20	23	29	8
Finance costs	23	13	12	5
Other Income	48	33	26	16
PBT	253	385	516	166
Tax Expense	50	82	116	38
PAT	203	303	400	128
<i>PAT Margin (%)</i>	<i>14.59%</i>	<i>15.72%</i>	<i>15.98%</i>	<i>16.35%</i>
Diluted EPS	8.81	13.13	15.44	4.17






# Historical Consolidated Balance Sheet

Particulars (INR Mn)	FY20	FY21	FY22
<b>EQUITY</b>	<b>646</b>	<b>942</b>	<b>2,277</b>
Equity Share Capital	77	77	307
Other Equity	569	865	1,970
<b>NON-CURRENT LIABILITIES</b>	<b>55</b>	<b>70</b>	<b>76</b>
a) Financial Liabilities			
i) Borrowings	19	19	12
b) Provisions	7	8	9
c) Deferred tax liabilities (net)	29	43	55
<b>CURRENT LIABILITIES</b>	<b>390</b>	<b>322</b>	<b>515</b>
a) Financial Liabilities			
i) Borrowings	270	183	332
ii) Trade Payables	72	80	106
iii) Other financial liabilities	14	7	6
b) Other current liabilities	33	43	59
c) Provisions	1	9	12
<b>TOTAL LIABILITIES</b>	<b>445</b>	<b>392</b>	<b>591</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,091</b>	<b>1,334</b>	<b>2,868</b>


Particulars (INR Mn)	FY20	FY21	FY22
<b>NON-CURRENT ASSETS</b>	<b>371</b>	<b>463</b>	<b>1,069</b>
a) Property, plant and equipment	312	376	527
b) Capital work-in-progress	31	37	97
c) Intangible assets	4	3	7
d) Financial assets			
i) Investments	-	2	2
ii) Other Financial Assets	14	18	351
e) Other non-current assets	10	27	85
<b>CURRENT ASSETS</b>	<b>720</b>	<b>871</b>	<b>1,799</b>
a) Financial Assets			
i) Trade Receivables	276	358	601
ii) Cash and cash equivalents	88	159	291
iii) Bank balances other than above	18	21	403
iv) Other financial assets	46	100	128
b) Other current assets	13	21	71
c) Inventories	279	212	305
<b>TOTAL ASSETS</b>	<b>1,091</b>	<b>1,334</b>	<b>2,868</b>

# Consolidated Financial Highlights


Operational Revenue (INR Mn)




EBIDTA (INR Mn) & EBITDA Margins (%)




PAT (INR Mn) & PAT Margins (%)




Net Debt to Equity (x)



Cash Conversion Cycle (Days)




ROCE (%) and ROE (%)






# Capital Market Information

### Share Price Movement (Upto 30<sup>th</sup> June, 2022)



Market Data (INR) as on 30 <sup>th</sup> June, 2022	
Face Value	10.0
CMP	264.4
52 Week H/L	648.0 / 231.3
Market Cap (INR Mn)	8127
Shares O/S (Mn)	30.7
Avg. Vol. Since Listing ('000)	301.5

### Shareholding Pattern as on 30<sup>th</sup> June, 2022





# Disclaimer

## **Sigachi Industries Limited Disclaimer:**

*No representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Sigachi Industries Limited (Sigachi), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.*

*Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.*

*This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.*

*This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.*

## **Valorem Advisors Disclaimer:**

*Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.*

**For further details, please feel free to contact our Investor Relations Representatives:**



Mr. Anuj Sonpal  
Valorem Advisors  
Tel: +91-22-4903-9500  
Email: [sigachi@valoremadvisors.com](mailto:sigachi@valoremadvisors.com)



Thank You

---